Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Hong L. Tiv"'
Autor:
Pratiti Bandopadhayay, Federica Piccioni, Ryan O’Rourke, Patricia Ho, Elizabeth M. Gonzalez, Graham Buchan, Kenin Qian, Gabrielle Gionet, Emily Girard, Margo Coxon, Matthew G. Rees, Lisa Brenan, Frank Dubois, Ofer Shapira, Noah F. Greenwald, Melanie Pages, Amanda Balboni Iniguez, Brenton R. Paolella, Alice Meng, Claire Sinai, Giovanni Roti, Neekesh V. Dharia, Amanda Creech, Benjamin Tanenbaum, Prasidda Khadka, Adam Tracy, Hong L. Tiv, Andrew L. Hong, Shannon Coy, Rumana Rashid, Jia-Ren Lin, Glenn S. Cowley, Fred C. Lam, Amy Goodale, Yenarae Lee, Kathleen Schoolcraft, Francisca Vazquez, William C. Hahn, Aviad Tsherniak, James E. Bradner, Michael B. Yaffe, Till Milde, Stefan M. Pfister, Jun Qi, Monica Schenone, Steven A. Carr, Keith L. Ligon, Mark W. Kieran, Sandro Santagata, James M. Olson, Prafulla C. Gokhale, Jacob D. Jaffe, David E. Root, Kimberly Stegmaier, Cory M. Johannessen, Rameen Beroukhim
Publikováno v:
Nature Communications, Vol 10, Iss 1, Pp 1-16 (2019)
BET-bromodomain inhibitors could be used to treat medulloblastoma tumors with Myc amplifications. Here, the authors show that both the response and resistance to BET inhibitors in mice is mediated by bHLH/homeobox transcription factors.
Externí odkaz:
https://doaj.org/article/f1ab52ee34d04a798436204eedf97a8a
Autor:
Charles W.M. Roberts, William C. Hahn, Stuart L. Schreiber, Elizabeth A. Stewart, Cory M. Johannessen, Prafulla C. Gokhale, Hong L. Tiv, Lauren Hoffmann, Kaley Blankenship, Burgess B. Freeman, Xiaofeng Wang, Andrew O. Giacomelli, Brinton Seashore-Ludlow, Pilar Ramos, Kaeli M. Mathias, Yiannis Drosos, Hsien-Chao Chou, Guillaume Kugener, Andrew L. Hong, Mariana DoCarmo, Lisa Brenan, Minh-Tam Pham, Taylor E. Arnoff, Matthew G. Rees, Elaine M. Oberlick, Thomas P. Howard
Raw data for follow-up xenograft studies. Note different tabs for each xenograft type.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11cf006969ed16c887b51d095fc8b4cf
https://doi.org/10.1158/1078-0432.22476111.v1
https://doi.org/10.1158/1078-0432.22476111.v1
Autor:
Charles W.M. Roberts, William C. Hahn, Loren D. Walensky, Kimberly Stegmaier, Peter J. Park, Prafulla C. Gokhale, Aviad Tsherniak, John M. Krill-Burger, April Cook, Katherine H. Walsh, Justin H. Hwang, Hong L. Tiv, Matthew G. Rees, Elaine M. Oberlick, Guillaume Kugener, Gregory H. Bird, Franziska Wachter, Ann M. Morgan, Minh-Tam Pham, Francisca Vazquez, Su Wang, Neekesh V. Dharia, Andrew L. Hong, Xiaofeng Wang, Andrew O. Giacomelli, Melinda R. Song, Taylor E. Arnoff, Thomas P. Howard
Malignant rhabdoid tumors (MRT) are highly aggressive pediatric cancers that respond poorly to current therapies. In this study, we screened several MRT cell lines with large-scale RNAi, CRISPR-Cas9, and small-molecule libraries to identify potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f5e63a84640452290fb3a73f322a7c2
https://doi.org/10.1158/0008-5472.c.6511541.v1
https://doi.org/10.1158/0008-5472.c.6511541.v1
Autor:
Charles W.M. Roberts, William C. Hahn, Stuart L. Schreiber, Elizabeth A. Stewart, Cory M. Johannessen, Prafulla C. Gokhale, Hong L. Tiv, Lauren Hoffmann, Kaley Blankenship, Burgess B. Freeman, Xiaofeng Wang, Andrew O. Giacomelli, Brinton Seashore-Ludlow, Pilar Ramos, Kaeli M. Mathias, Yiannis Drosos, Hsien-Chao Chou, Guillaume Kugener, Andrew L. Hong, Mariana DoCarmo, Lisa Brenan, Minh-Tam Pham, Taylor E. Arnoff, Matthew G. Rees, Elaine M. Oberlick, Thomas P. Howard
Purpose:Rhabdoid tumors are devastating pediatric cancers in need of improved therapies. We sought to identify small molecules that exhibit in vitro and in vivo efficacy against preclinical models of rhabdoid tumor.Experimental Design:We screened eig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ea9a68f47fd3df93b1ed379bcbf43b5
https://doi.org/10.1158/1078-0432.c.6529299.v1
https://doi.org/10.1158/1078-0432.c.6529299.v1
Autor:
Charles W.M. Roberts, William C. Hahn, Loren D. Walensky, Kimberly Stegmaier, Peter J. Park, Prafulla C. Gokhale, Aviad Tsherniak, John M. Krill-Burger, April Cook, Katherine H. Walsh, Justin H. Hwang, Hong L. Tiv, Matthew G. Rees, Elaine M. Oberlick, Guillaume Kugener, Gregory H. Bird, Franziska Wachter, Ann M. Morgan, Minh-Tam Pham, Francisca Vazquez, Su Wang, Neekesh V. Dharia, Andrew L. Hong, Xiaofeng Wang, Andrew O. Giacomelli, Melinda R. Song, Taylor E. Arnoff, Thomas P. Howard
Expanded methodological detail on large-scale data analysis (RNAi, CRISPR-Cas9, p53 status annotations, RNA-seq, and primary tumor expression).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f609b17191e1f0d97eeabf7e23b6ca7
https://doi.org/10.1158/0008-5472.22423640
https://doi.org/10.1158/0008-5472.22423640
Autor:
Charles W.M. Roberts, William C. Hahn, Loren D. Walensky, Kimberly Stegmaier, Peter J. Park, Prafulla C. Gokhale, Aviad Tsherniak, John M. Krill-Burger, April Cook, Katherine H. Walsh, Justin H. Hwang, Hong L. Tiv, Matthew G. Rees, Elaine M. Oberlick, Guillaume Kugener, Gregory H. Bird, Franziska Wachter, Ann M. Morgan, Minh-Tam Pham, Francisca Vazquez, Su Wang, Neekesh V. Dharia, Andrew L. Hong, Xiaofeng Wang, Andrew O. Giacomelli, Melinda R. Song, Taylor E. Arnoff, Thomas P. Howard
S1: Sources, media, and other information on all cell lines. S2: p53 status annotations for all cell lines. S3: sgRNA sequences for TP53 inactivation. S4: Primers for TP53 allele screening and RT-qPCR. S5: Sources, catalog numbers, and dilutions of a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4f07dc29b82807b45137b69ceee2be3
https://doi.org/10.1158/0008-5472.22423637
https://doi.org/10.1158/0008-5472.22423637
Autor:
Charles W.M. Roberts, William C. Hahn, Stuart L. Schreiber, Elizabeth A. Stewart, Cory M. Johannessen, Prafulla C. Gokhale, Hong L. Tiv, Lauren Hoffmann, Kaley Blankenship, Burgess B. Freeman, Xiaofeng Wang, Andrew O. Giacomelli, Brinton Seashore-Ludlow, Pilar Ramos, Kaeli M. Mathias, Yiannis Drosos, Hsien-Chao Chou, Guillaume Kugener, Andrew L. Hong, Mariana DoCarmo, Lisa Brenan, Minh-Tam Pham, Taylor E. Arnoff, Matthew G. Rees, Elaine M. Oberlick, Thomas P. Howard
Combined supplementary figures with accompanying legends.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::477cd833910a34100dbb7c02a3286cc0
https://doi.org/10.1158/1078-0432.22476123
https://doi.org/10.1158/1078-0432.22476123
Autor:
Charles W.M. Roberts, William C. Hahn, Loren D. Walensky, Kimberly Stegmaier, Peter J. Park, Prafulla C. Gokhale, Aviad Tsherniak, John M. Krill-Burger, April Cook, Katherine H. Walsh, Justin H. Hwang, Hong L. Tiv, Matthew G. Rees, Elaine M. Oberlick, Guillaume Kugener, Gregory H. Bird, Franziska Wachter, Ann M. Morgan, Minh-Tam Pham, Francisca Vazquez, Su Wang, Neekesh V. Dharia, Andrew L. Hong, Xiaofeng Wang, Andrew O. Giacomelli, Melinda R. Song, Taylor E. Arnoff, Thomas P. Howard
S1: RNAi data and CRISPR-Cas9 data divided by p53 status. S2: Expression of MDM2 and MDM4 in MRT and control cell lines. S3: CRISPR-Cas9 mediated inactivation of TP53 in MRT cell lines. S4: Immunoblots for p53 pathway activation upon MDM2 and MDM2/4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a151ac00f0d833b79c317c293929d21
https://doi.org/10.1158/0008-5472.22423643.v1
https://doi.org/10.1158/0008-5472.22423643.v1
Autor:
Margaret K. Wilkens, Monica Musteanu, Aine Knott, Magda Bahcall, Shripad V. Bhagwat, Kara M. Soroko, Prafulla C. Gokhale, Jens Köhler, Emily S. Chambers, Mika Lin, Yutong Zhao, Hong L. Tiv, Jihyun Choi, Jason Manro, Ramon V. Tiu, Arrien A. Bertram, Pasi A. Jänne, Atsuko Ogino, Cloud P. Paweletz, Jiaqi Li, Chiara Ambrogio
Publikováno v:
Molecular Cancer Therapeutics. 20:641-654
RAS gene mutations are the most frequent oncogenic event in lung cancer. They activate multiple RAS-centric signaling networks among them the MAPK, PI3K, and RB pathways. Within the MAPK pathway, ERK1/2 proteins exert a bottleneck function for transm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92b52a75d6e0156073726473d7d901c2
https://doi.org/10.1158/1535-7163.mct-20-0531
https://doi.org/10.1158/1535-7163.mct-20-0531
Autor:
Sara J. Buhrlage, Xiaoxi Liu, Jing Yang, Jinhua Wang, Abigail E Case, Sophia Adamia, Richard Stone, Chengcheng Meng, Prafulla C. Gokhale, Nathanael S. Gray, Ellen Weisberg, James D. Griffin, Hong L. Tiv, Martin Sattler
Publikováno v:
Journal of Cellular and Molecular Medicine
Recently, several targeted agents have been developed for specific subsets of patients with acute myeloid leukaemia (AML), including midostaurin, the first FDA‐approved FLT3 inhibitor for newly diagnosed patients with FLT3 mutations. However, in th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9b94066f50c52e1dc6c57cf1a73e7e
https://doi.org/10.1111/jcmm.14927
https://doi.org/10.1111/jcmm.14927